550999-74-1 Usage
Description
EVP-6124 (hydrochloride) is a compound that has been developed for its potential therapeutic applications, particularly in the treatment of cognitive impairments associated with Alzheimer's disease and schizophrenia. It functions as a selective partial agonist of the a7 nicotinic acetylcholine receptor, which plays a crucial role in cognitive processes.
Uses
Used in Pharmaceutical Industry:
EVP-6124 (hydrochloride) is used as a therapeutic agent for the treatment of cognitive impairment in patients with Alzheimer's disease and schizophrenia. Its mechanism of action involves modulating the a7 nicotinic acetylcholine receptor, which is implicated in cognitive function, potentially leading to improvements in memory, attention, and other cognitive abilities affected by these conditions.
Additionally, as a selective partial agonist, EVP-6124 (hydrochloride) may offer a more targeted approach to treatment with potentially fewer side effects compared to other drugs that may have a broader impact on the nervous system. This selective action could make it a valuable addition to the arsenal of medications available for the treatment of cognitive impairments in Alzheimer's disease and schizophrenia.
Check Digit Verification of cas no
The CAS Registry Mumber 550999-74-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 5,5,0,9,9 and 9 respectively; the second part has 2 digits, 7 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 550999-74:
(8*5)+(7*5)+(6*0)+(5*9)+(4*9)+(3*9)+(2*7)+(1*4)=201
201 % 10 = 1
So 550999-74-1 is a valid CAS Registry Number.
550999-74-1Relevant articles and documents
Optimized synthesis and solid state investigations on the drug candidate encenicline hydrochloride
Laus, Gerhard,Neuner, Sandro,Metz, Ramona,Müller, Thomas,Kahlenberg, Volker,Gelbrich, Thomas,Nerdinger, Sven,Schreiner, Erwin,Adamer, Verena,Wurst, Klaus,Schottenberger, Herwig
, p. 1226 - 1238 (2019/08/01)
For the production of drug substances a robust, scalable process delivering the active pharmaceutical ingredient (API) in excellent chemical and polymorphic purity is required. For this purpose we developed a novel imidazole-mediated one-pot procedure for
New crystal forms of (R)-7-chloro-N-(quinuclidinyl-3-yl)benzo[b]thienyl-2-formamide hydrochloride
-
Paragraph 0068; 0069; 0070; 0071; 00725, (2017/01/02)
The invention relates to new crystal forms of (R)-7-chloro-N-(quinuclidinyl-3-yl)benzo[b]thienyl-2-formamide hydrochloride and a preparation method thereof. The crystal forms provided by the invention have the advantages of favorable stability, lower hygroscopicity, developable technique, high treatability and the like. The preparation method is simple, is low in cost, and has important value for optimizing and developing the drug in future.
